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PKM2 regulates endothelial 
cell junction dynamics and 
angiogenesis via ATP production
Jesús Gómez-Escudero1,2, Cristina Clemente1,3, Diego García-Weber4, Rebeca Acín-Pérez5, 
Jaime Millán4, José A. Enríquez  5, Katie Bentley6,7, Peter Carmeliet8,9,10 & Alicia G. Arroyo  1,3*
Angiogenesis, the formation of new blood vessels from pre-existing ones, occurs in pathophysiological 
contexts such as wound healing, cancer, and chronic inflammatory disease. During sprouting 
angiogenesis, endothelial tip and stalk cells coordinately remodel their cell-cell junctions to allow 
collective migration and extension of the sprout while maintaining barrier integrity. All these processes 
require energy, and the predominant ATP generation route in endothelial cells is glycolysis. However, 
it remains unclear how ATP reaches the plasma membrane and intercellular junctions. In this study, 
we demonstrate that the glycolytic enzyme pyruvate kinase 2 (PKM2) is required for sprouting 
angiogenesis in vitro and in vivo through the regulation of endothelial cell-junction dynamics and 
collective migration. We show that PKM2-silencing decreases ATP required for proper VE-cadherin 
internalization/traffic at endothelial cell-cell junctions. Our study provides fresh insight into the role of 
ATP subcellular compartmentalization in endothelial cells during angiogenesis. Since manipulation of 
EC glycolysis constitutes a potential therapeutic intervention route, particularly in tumors and chronic 
inflammatory disease, these findings may help to refine the targeting of endothelial glycolytic activity 
in disease.
Angiogenesis, the formation of new blood vessels from pre-existing ones, occurs in pathophysiological contexts 
such as wound healing, cancer and chronic inflammatory disease. In sprouting angiogenesis, endothelial cells 
(ECs) receive a stimulus (usually VEGFA) which triggers the angiogenic response by the selection and specifi-
cation of the endothelial tip cell1. This cell migrates toward the stimulus followed by the stalk cells, defined by 
a balanced Dll4/VEGFA signaling2. A fine-tuned coordination of diverse cellular responses is necessary at this 
initial step, including reorganization of endothelial cell junctions, tip-cell migration to generate characteristic 
cytoskeletal protrusions called filopodia, and proliferation and lumenization by stalk cells. Impairment in any of 
these processes prevents productive angiogenesis and the formation of a functional vascular plexus3–5. A shared 
feature of all these endothelial cell responses is the need for energy in the form of ATP6,7.
The predominant ATP generation route in ECs is glycolysis8, providing both the ATP required for cell func-
tion and the intermediate metabolites that feed into other metabolic pathways for macromolecule biosynthesis9,10. 
During sprouting angiogenesis, glycolysis is boosted in the endothelial tip cell, and angiogenesis is blunted by 
the genetic deletion or pharmacological inhibition of glycolytic enzymes like PFKFB311–13. Recent dissection 
of the impact of distinct metabolic routes in endothelial cells has revealed that glycolysis impacts endothelial 
1Vascular Pathophysiology, Centro Nacional de Investigaciones Cardiovasculares (CNIC). Melchor Fernández 
Almagro 3, 28029, Madrid, Spain. 2Tumour Biology Department, Barts Cancer Institute, John´s Vane Centre, Queen 
Mary´s University of London. Charterhouse Sq, EC1M 6BQ, London, UK. 3Centro de Investigaciones Biológicas (CIB-
CSIC). Ramiro de Maeztu 9, 28040, Madrid, Spain. 4Centro de Biología Molecular Severo Ochoa, Consejo Superior de 
Investigaciones Científicas (CSIC), Universidad Autónoma de Madrid, 28049, Madrid, Spain. 5Myocardial Pathology 
Areas, Centro Nacional de Investigaciones Cardiovasculares (CNIC). Melchor Fernández Almagro 3, 28029, Madrid, 
Spain. 6Computational Biology Laboratory, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, 
MA, USA. 7Cellular Adaptive Behaviour Laboratory, Rudbeck Laboratories, Department of Immunology, Genetics 
and Pathology, Uppsala University, Uppsala, Sweden. 8Laboratory of Angiogenesis and Vascular Metabolism, 
Center for Cancer Biology, Vlaams Instituut voor Biotechnologie (VIB), B-3000, Leuven, Belgium. 9Laboratory of 
Angiogenesis and Vascular Metabolism, Center for Cancer Biology, Department of Oncology, University of Leuven, 
B-3000, Leuven, Belgium. 10State Key Laboratory of Ophthalmology, Zhongsan Ophthalmic Center, Sun Yat-Sen 
University, Guangzhou, China. *email: agarroyo@cib.csic.es
open
2Scientific RepoRtS |         (2019) 9:15022  | https://doi.org/10.1038/s41598-019-50866-x
www.nature.com/scientificreportswww.nature.com/scientificreports/
cell migration (in addition to proliferation), whereas fatty-acid oxidation and amino-acid metabolism support 
nucleotide and protein synthesis14. These recent discoveries have opened new avenues for possible therapeutic 
modulation of EC metabolism in cancer and chronic inflammatory disease15.
Glycolysis is classically viewed as occurring in the cytosol, with ATP diffusing throughout the cell to reach dis-
tant locations such as plasma membrane protrusions and intercellular junctions. ATP diffusion to cell-membrane 
locations is often limited by the long distances involved and obstruction by the packed cytoskeleton16,17. 
Pioneering studies showed the anchoring of glycolytic enzymes to the erythrocyte plasma membrane18, and more 
recent evidence supports the subcellular compartmentalization of glycolytic and ATP-producing enzymes in 
other cell types19. Examples of this type of local ATP production include the regulation of vesicle traffic along 
microtubules in neurons by GAPDH20, actin cytoskeleton reorganization at lamellipodia by PFKFB311, and 
the establishment and stability of endothelial cell-cell contacts by the nucleoside-diphosphate kinase (NDPK) 
NM236. These findings indicate that compartmentalization of ATP-producing enzymes is a general mechanism 
governing spatio-temporal cellular events21. How this ATP compartmentalization occurs is, however, incom-
pletely understood.
During glycolysis, the enzyme pyruvate kinase (PK) is in charge of catalyzing the last step, which converts 
phosphoenolpyruvate to pyruvate with the generation of one molecule of ATP. PK has three forms: L (liver), 
R (erythrocytes), and M (muscle). The M form is expressed in most human organs and has two isoforms, M1 
and M2, regulated by alternative splicing of the PKM gene22. The M1 and M2 isoforms differ in the regulation 
of their catalytic activity, with PKM1 constitutively active and PKM2 subject to regulation22–25. PKM2 function 
has mainly been analyzed in cancer and inflammation26,27. Although PKM2 was considered a master regulator of 
proliferation, particularly in tumor cells, recent studies have established that the primary cause of cell-cycle arrest 
in PKM2-null mice or PKM2-depleted cells is compensatory overexpression of PKM127,28. Protein kinase actions 
have also been linked to PKM2, although the direct contribution of PKM2 and the importance of this activity 
remain unresolved29,30. In the context of angiogenesis, soluble PKM2 dimers released by tumor cells have been 
reported to increase endothelial cell-tube formation by increasing cell proliferation, migration, and extracellular 
matrix adhesion; however, the mechanisms of these PKM2 extracellular actions remain unclear31. More recently, 
JMDM8 was shown to regulate human EC sprouting and metabolism through its association with PKM2, but the 
impact of JMDM8 silencing was only analyzed in the sprout spheroid assay, and no mechanisms were defined32. 
In this study, we explore PKM2 actions in sprouting angiogenesis in vitro and in vivo and decipher the role of 
PKM2 subcellular compartmentalization in this process.
Results
PKM2 is required for sprouting angiogenesis in vitro and in vivo. To characterize the role of PKM2 
in ECs during sprouting angiogenesis, we specifically silenced PKM2 expression in human umbilical vein ECs 
(HUVEC) with an isoform-specific siRNA that decreased PKM2 expression without affecting PKM1 levels 
(Fig. 1A). In the spheroid culture system used to study sprouting angiogenesis, suppression of PKM2 expres-
sion was maintained up to the final time point (day 7) (Supplementary Figure S1A,B). Although sprouts devel-
oped a proper lumen in both groups (Supplementary Figure S1C), PKM2-silenced EC spheroids produced fewer 
and shorter sprouts than spheroids formed by control siRNA-transfected ECs (Fig. 1B–D). Silencing PKM2 also 
resulted in reduced number and shorter endothelial tubes in the ‘hanging drop’ assay, which runs for 24 hours 
(Supplementary Figure S1D,E). Moreover, sprouts formed by control and PKM2-silenced EC spheroids con-
tained similar proportions of Ki67+ proliferating cells, and tip cells in these spheroids produced fewer filopodia 
(Fig. 1E–H). Silencing PKM2 with an independent siRNA in mouse lung ECs also impaired sprout formation in 
the spheroids confirming the need of PKM2 for in vitro sprouting angiogenesis (Supplementary Figure S1F,G).
To determine whether PKM2 was also required for sprouting angiogenesis in vivo, P6 mice were given an 
intravitreal injection of PKM2 siRNA, and we examined the retinal vasculature after 72 h. Western blot of ret-
ina extracts showed reduced PKM2 protein expression, and immunofluorescence analysis confirmed decreased 
PKM2 in the vasculature (Fig. 2A,B). PKM2-silencing in retina diminished radial vascular growth with no impact 
on vascular density (Fig. 2C–E). This prompted us to analyze EC number and proliferation. PKM2-silenced 
and control-siRNA treated retinas had similar densities of ERG+ cells and the same proportion of Ki67+ ECs 
(Fig. 2F–I). Matching the in vitro analysis, filopodia number was lower in PKM2-silenced retinas (Fig. 2J,K). 
Together, these observations show that PKM2 is required for sprouting angiogenesis in vitro and in vivo by mech-
anisms that do not seem to involve EC proliferation.
PKM2 is located at VE-cadherin-expressing endothelial cell junctions. Although PKM2 was mostly 
found in the cytoplasm of ECs, high-resolution confocal microscopy images, image deconvolution and profile inten-
sity analysis revealed however that a pool of PKM2 localized close to VE-cadherin and cortical F-actin at the junc-
tions (Fig. 3A,B). We confirmed PKM2 vicinity to VE-cadherin at the endothelial junctions by proximity ligation 
assays (Fig. 3C). Moreover, in spite of similar PKM2 protein levels, PKM2 was barely observed at the junctions of 
VE-cadherin-null endothelial cells compared to VE-cadherin-positive ones (Fig. 3D,E). PKM2 was also found nearby 
the junctions of ECs stimulated with sphingosine-1-phosphate (S1P), an inducer of EC junction remodeling and rein-
forcement33 (Supplementary Figure S2A), and of 3D EC sprouts in vitro (Fig. 3F), without significant differences in 
PKM2 presence at the junctions of tip and stalk cells (PKM2 MFItip = 144.4 ± 22.82 and MFIstalk = 156.3 ± 20.3, n = 19 
sprouts). PKM2 was also detected at F-actin-rich filopodia and lamellipodia of migrating ECs in 3D and 2D respec-
tively (Supplementary Figure S2B,C), in line with the reported PKM2/F-actin association34.
In accordance with the immunofluorescence data, PKM2 was found by western blot in both cytosolic and 
membrane EC fractions and the specificity of this compartmentation was shown by reduced PKM2 abundance in 
the membrane fraction of PKM2-silenced ECs (Fig. 3G). Cell membrane subfractionation further revealed that 
PKM2 was present in low-density fractions containing plasma membrane and in endosomes (Fig. 3H).
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PKM2-silencing destabilizes junctions and impairs EC collective migration. Productive angio-
genesis depends on VE-cadherin-mediated EC junction stability and dynamics35,36. We therefore investigated 
the influence of PKM2 on EC-junctional VE-cadherin at baseline and upon junction remodeling induced by S1P. 
Figure 1. PKM2 is required for in vitro endothelial cell sprouting. (A) Western blot of PKM2 and PKM1 
expression 72 hours after siRNA silencing in HUVECs and quantification versus tubulin included as a loading 
control; means ± SEM, n = 3, ns non-significant, **p < 0.01 by unpaired Student t-test. (B) Bright-field 
microscopy images of spheroids coated with HUVECs transfected with control or PKM2 siRNA and embedded 
in fibrin gels for 7 days. Scale bar, 10 µm. (C) Sprout length in 3D spheroids; means ± SEM, n = 103 and 38 
spheroids formed by control and PKM2 siRNA-silenced cells from one representative experiment of five 
performed, ****p < 0.0001 by unpaired Student t-test. (D) Sprout numbers in 3D spheroids; means ± SEM, 
n = 27 and 14 spheroids formed by control and PKM2 siRNA-silenced cells from one experiment representative 
of five performed, **p < 0.01 by unpaired Student t-test. (E) Immunofluorescence of Ki67 (red, proliferation) 
and Hoechst (blue, nuclei) in 3D spheroid sprouts. Scale bar, 10 µm. (F) Percentage of Ki67-positive cells per 
sprout in 3D spheroids; means ± SEM, n = 3 independent experiments, ns non-significant by paired Student 
t-test. (G) Immunofluorescence of F-actin in 3D spheroid sprouts. Scale bar, 10 µm. (H) Filopodia number in 
3D spheroids; means ± SEM, n = 13 and 15 filopodia in sprouts formed by control and PKM2 siRNA-silenced 
cells from one representative experiment of five performed, ***p < 0.0001 by Welch´s test. MW, molecular 
weight. See also Figure S1.
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Figure 2. PKM2 silencing results in reduced vascular growth and filopodia number in the postnatal mouse 
retina. (A) Western blot of PKM2 and PKM1 expression in protein extracts from mouse retinas obtained 
72 hours after intravitreal siRNA-injection. GAPDH is included as a loading control; n = 3 mice per condition. 
(B) Immunofluorescence of isolectin B4 (red, vessels), PKM2 (green), and nuclei (blue, Hoechst) in whole-
mount P6 mouse retinas 72 hours after intravitreal siRNA-injection. Scale bar, 10 µm. (C) Immunofluorescence 
of isolectin B4 (green, vessels) in whole-mount P6 mouse retinas 72 hours after intravitreal siRNA-injection. 
Scale bar, 50 µm. Disconnected Erg/IB4-positive structures correspond to rests of hyaline membrane fragments. 
(D) Radial vascular growth in mouse retinas (P6) 72 hours after intravitreal siRNA-injection, means ± SEM, 
n = 8 mice per condition, ***p < 0.001 by Mann-Whitney test. (E) Vascular density in mouse retinas (P6) 
72 hours after intravitreal siRNA-injection, means ± SEM, n = 4 mice per condition, ns non-significant by 
unpaired Student t-test. (F) Immunofluorescence ERG (white, endothelial cell nuclei) in whole-mount P6 
mouse retinas 72 hours after intravitreal siRNA-injection. Scale bar, 50 µm. (G) ERG positive cells per vessel 
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In spite of no change in total VE-cadherin protein expression, PKM2-silenced ECs showed lower cell-junction 
VE-cadherin intensity than control ECs, together with a higher proportion of discontinuous junctions at baseline 
and after S1P treatment (Fig. 3I–M and Supplementary Figure S2D–F). Junctions formed by PKM2-silenced 
ECs also showed a clear decrease in plakoglobin, a marker of stable VE-cadherin cell-cell contacts (Fig. 3N and 
Supplementary Figure S2G). Indeed, PKM2-silencing with an independent siRNA confirmed a similar altered 
junctional VE-cadherin pattern in mouse lung ECs (Supplementary Figure 2H–J). Finally, PKM2-silenced cells 
showed a weakened response to S1P-driven reinforcement of the EC barrier, as indicated by lower transendothe-
lial electrical resistance (TEER) values (Fig. 3O). These data indicate defects in VE-cadherin–mediated EC barrier 
in the absence of PKM2 in remodeling conditions.
A recognized function of VE-cadherin at cell-cell junctions is to conduct polarity signals while maintain-
ing barrier integrity during collective migration36. In line with the observed junctional defects, PKM2-silenced 
HUVECs were significantly less efficient than control siRNA-transfected ECs at closing the wound area in the 
scratch assay without showing differences in cell proliferation (Fig. 4A–D). Accordingly, inhibition of prolifera-
tion did not change the defective wound closure and PKM2 silencing did not affect EC basal growth and prolifer-
ation (Supplementary Figure S3A–D). We next assessed the role of PKM2 in the orientation and directionality of 
migrating EC cells by quantifying Golgi apparatus polarization and by time-lapse microscopy37,38. PKM2-silenced 
migrating EC cultures showed more discontinuous junctions and this correlated with a higher proportion of cells 
polarized against the wound than control cultures (Fig. 4E–G). Time-lapse recording and single-cell track analy-
sis confirmed that PKM2-silenced ECs migrated faster and for longer linear (Euclidean) distances opposite to the 
wound but for shorter distances and less directional toward the wound compared with controls (Fig. 4H–J and 
Movies S1–S2). Moreover, PKM2 silencing impaired collective migration of adjacent endothelial cells (Fig. 4K).
PKM2 is required for endothelial cell junction remodeling during angiogenic sprouting in vitro 
and in vivo. In addition to maintenance of junction stability and to collective migration in 2D, VE-cadherin 
dynamics are also essential for functional EC arrangements during 3D sprouting angiogenesis, and this manifests 
as a balanced distribution of stable and unstable EC junctions35. To determine the role of PKM2 in regulating 
this mosaicism, we quantified the distribution of EC junction patches by classifying the morphology of EC junc-
tions based on their VE-cadherin pattern, from discontinuous (active/unstable) to continuous (inactive/stable) 
according to the reported ‘patching algorithm’35. The 3D sprouts formed in vitro by PKM2-silenced human ECs 
showed an altered EC-junction patch distribution, with a higher abundance of patches containing active/unstable 
junctions than 3D sprouts formed by control siRNA-transfected ECs; this was reflected by a change in the active/
unstable:inactive/stable patch ratio (Fig. 5A–D). This phenotype was also confirmed in vivo in the vasculature of 
PKM2-silenced postnatal retinas (Fig. 5E–G).
PKM2 activity is involved in the regulation of EC junctions and sprouting angiogenesis. In 
addition to its action in glycolysis, PKM2 has been linked to non-glycolytic functions29,30. To determine whether 
the effects of PKM2 absence on EC junctions and sprouting angiogenesis are related to pyruvate kinase activity, 
we treated ECs with shikonin, a specific inhibitor of the PKM2 isoform39. Pharmacological inhibition of PKM2 
activity increased the number of discontinuous junctions in basal and S1P-treated human ECs (Supplementary 
Figure S4A,B) and recapitulated the rest of effects of PKM2-silencing. Shikonin reduced the number and length 
of sprouts in the 3D spheroid assay and impaired wound closure and EC collective migration without influencing 
EC proliferation (Supplementary Figure S4C–G and Movies S3-S4). In contrast, the general glycolysis inhibitor 
2-deoxyglucose (2-DG), in addition to impairing junction stability and EC migration, also decreased EC pro-
liferation (Supplementary Figure S4H–K). PKM2 activity was also required in vivo since intravitreal injection 
of shikonin reduced vascular radial growth and filopodia number in P6 mice while having no effect on vascular 
density, EC number, or the percentage of proliferating ECs, thus reproducing the phenotype observed in the 
vasculature of PKM2-silenced retinas (Supplementary Figure S5A–I). Intravitreal shikonin injection also shifted 
the active/unstable:inactive/stable junction ratio by increasing the proportion of active junctions in the P6 retinal 
vasculature (Supplementary Figure S5J–L).
PKM2-silencing decreases ATP nearby EC junctions. Given the requirement of PKM2 kinase activ-
ity for its actions on EC junctions and sprouting angiogenesis, we next assessed the impact of PKM2 on EC 
ATP production. Analysis of the global metabolic state revealed that PKM2-silenced ECs had a lower glycoly-
sis flux than control siRNA-transfected cells, revealed by a relative ~20% drop in the extracellular acidification 
ratio (ECAR) (Fig. 6A). This was reflected in significantly lower total ATP production (Fig. 6B). Mitochondrial 
area in P6 mouse retinas 72 hours after intravitreal siRNA-injection, means ± SEM, n = 4 mice per condition, 
ns non-significant by unpaired Student t-test. (H) Immunofluorescence of isolectin B4 (blue, vessels), Ki67 
(green, proliferation), and ERG (red, endothelial cell nuclei) in whole-mount P6 mouse retinas 72 hours after 
intravitreal siRNA-injection. Scale bar, 10 µm. (I) Percentage of Ki67-positive cells per total ERG-positive cells 
in P6 mouse retinas 72 hours after intravitreal siRNA-injection; means ± SEM, n = 4 mice per condition, ns 
non-significant by unpaired Student t-test. (J) Immunofluorescence of isolectin B4 (white, vessels) in whole-
mount P6 mouse retinas 72 hours after intravitreal siRNA-injection. Each yellow asterisk marks one filopodia. 
Scale bar, 10 µm. (K) Number of filopodia per 100 μm of vascular front in P6 mouse retinas 72 hours after 
intravitreal siRNA-injection; means ± SEM, n = 4 mice per condition, *p < 0.05 by unpaired Student t-test. MW, 
molecular weight.
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Figure 3. PKM2 is localized at VE-cadherin junction compartment. (A) Immunofluorescence of PKM2 
(green), VE-cadherin (red) and F-actin (grey) in confluent HUVECs; single color and merged images are 
shown. Magnified views and de-convolved images of boxed areas below. Scale bars, 10 µm and 5 µm in the 
magnified views. (B) RGB (red, green, blue) profile of PKM2 (green), VE-cadherin (red) and F-actin (blue) 
intensity at areas of the endothelial cell junction marked by the yellow lines in A. (C) Representative merged 
images of Hoechst (blue) and proximity ligation assay (PLA, green) for PKM2 and VE-cadherin (left) and 
together with F-actin (grey; right) in HUVECs. PLA of rabbit and goat IgGs is also shown (negative). Scale 
bar, 10 µm. (D) Immunofluorescence of PKM2 (green), VE-cadherin (red) and CD31 (grey) in confluent VE-
cadherin-expressing (VEC-pos) and VE-cadherin–deficient (VEC-null) mouse endothelial cells; single color 
and merged images of green and red channels are shown. Scale bar, 10 µm. (E) Western blot of VE-cadherin 
and PKM2 in lysates from VEC-pos and VEC-null endothelial cells. Tubulin is included as a loading control. 
MW, molecular weight. (F) Immunofluorescence of PKM2 (green), VE-cadherin (red) and F-actin (grey) in 
3D spheroid sprouts. Scale bar, 10 µm. (G) Western blot of PKM2 in total lysate and in cytosol and membrane 
fractions of confluent HUVECs treated with S1P or vehicle (left) and transfected with control or PKM2. VE-
cadherin and Rho-GDI are included as markers of plasma membrane and cytosol. MW, molecular weight. 
(H) Western blot of PKM2 in membrane subfractions obtained from confluent HUVECs by density gradient 
centrifugation. VE-cadherin and EEA1 are included as markers of plasma membrane and endosomes. MW, 
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activity remained intact, with similar basal and maximal oxygen consumption ratios (OCR) in PKM2 and control 
siRNA-silenced human ECs (Fig. 6C,D).
Following the protocol reported for other glycolytic enzymes16,20, we next performed sequential cell lysis with 
increasing proportions of saponin to allow the extraction of two fractions, one enriched for cytosol and the other 
less soluble for cytoskeleton and EC junctions (CSK-junction enriched) (Fig. 6E,F). Pyruvate kinase activity was 
~1.8-fold higher in the CSK-junction enriched sub-fraction than in the cytosol; specificity for PKM2 was con-
firmed by decreased PK activity in both compartments when PKM2 expression was silenced (Fig. 6G).
To assess whether PKM2-silencing impaired local ATP levels, particularly at CSK-junction compartment, 
we quantitated ATP in saponin-extracted sub-fractions. PKM2-silencing in mouse and human ECs significantly 
decreased ATP production in the cytosol, by ~50%, and the CSK-junction enriched sub-fraction, by ~40% 
(Supplementary Figure S6A and Fig. 6H), in accordance with the reduced PK activity (Fig. 6G). To ensure quan-
tification of ATP levels nearby EC junctions, we transduced HUVECs with lentivirus encoding the FRET-based 
ATP sensor GO-ATeam140. PKM2 silencing resulted in a significant reduction in the GO-ATeam1 FRET signal 
at both cytosol and junctions (as in subcellular fraction analysis), but the ratio of ATP levels at junctions versus 
cytosol was significantly decreased indicating a major impact of PKM2 absence on ATP levels at the junctional 
region of 2D human EC monolayers (Fig. 6I,J). We observed similar results in GO-ATeam1-transduced HUVEC 
when PKM2 activity was inhibited by shikonin in line with the reduction of ATP levels in the CSK-junction 
fraction (Supplementary Figure S6B,C). These findings indicate that PKM2-silencing reduces ATP levels nearby 
EC junctions.
PKM2 and local ATP regulate VE-cadherin dynamics and internalization at EC junctions. We 
next explored whether reduced ATP production in the CSK-junction compartment in PKM2 absence/inhibition 
may affect VE-cadherin turnover41. Gradient sub-fractionation experiments revealed that PKM2 inhibition by 
shikonin increased the proportion of VE-cadherin present at the plasma membrane versus endosomes compared 
to control ECs (Supplementary Figure S6D).
Live imaging of HUVEC transduced with lentivirus coding for VE-cadherin-EGFP or LifeAct-EGFP in basal 
conditions and after stimulation with VEGFA allowed us to analyze VE-cadherin, and F-actin dynamics at EC 
junctions42. Time-lapse microscopy of VE-cadherin-EGFP-expressing HUVEC showed that PKM2 inhibition by 
shikonin led to increased numbers of inter-cellular gaps mostly after VEGFA treatment compared to control ECs 
(Fig. 7A,C; Movies S5–S8); similar gaps were observed in VE-cadherin-EGFP-transduced HUVEC silenced for 
PKM2 (Supp Figure S6E and Movies S9–S10). These data confirmed the enhanced junction instability observed 
in 2D endothelial monolayers in static conditions (Fig. 3H–M). In LifeAct-EGFP-expressing ECs, we visual-
ized small active F-actin protrusions in the lateral border preceding VE-cadherin ‘plaques’ and corresponding 
to ‘junction-associated intermittent lamellipodia’ (JAIL), which increased in size and persistence after VEGFA 
stimulation in control cells as reported42 (Movies S11–S14). Notably, PKM2 inhibition by shikonin significantly 
reduced the number of JAIL and VE-cadherin plaques in untreated and VEGFA-stimulated cells compared to 
controls (Fig. 7A,B,D,E).
We next investigated directly the impact of PKM2 inhibition on VE-cadherin internalization in basal 
conditions and after stimulation with VEGFA. VEGFA-triggered VE-cadherin internalization is a classic 
clathrin-dependent/ATP-consuming event43,44. Notably, PKM2 silencing in ECs led to a significant reduction 
of VEGFA-induced VE-cadherin internalization compared to controls (Fig. 7F,G), arguing for decreased local 
ATP level as a mediator of such effect. We obtained a similar phenotype in human ECs treated with shikonin 
(Supplementary Figure S6F).
Our data support a model in which PKM2 absence/inhibition reduces ATP levels nearby endothelial junc-
tions thus hindering VE-cadherin clathrin-mediated internalization and JAlL formation and overall resulting in 
impaired junction remodeling, collective migration, and angiogenic sprouting.
Discussion
This study presents the first description of the impact of subcellular compartmentalization of PKM2 on ATP lev-
els, VE-cadherin internalization and EC junction rearrangements, and sprouting angiogenesis in vitro and in vivo.
PKM2 expression has been correlated with cell proliferation, particularly in tumor cells26. Our data estab-
lish that PKM2 is not required for EC proliferation, since PKM2-silenced and shikonin-treated ECs showed 
no differences from controls in vitro or in vivo. Despite the proposed role of PKM2 in cancer-cell proliferation, 
recent findings from Vander Heiden’s group and others indicate that cell-cycle arrest in the absence of PKM2 is 
likely driven by compensatory PKM1 upregulation27. In this study, PKM2-null mice displayed distinct patterns of 
molecular weight. (I) Western blot and quantification of VE-cadherin in HUVECs transfected with control 
or PKM2 siRNA. Tubulin is included as a loading control. Means ± SEM, n = 3 independent experiments, ns 
non-significant by unpaired Student t-test. (J) Immunofluorescence of VE-cadherin (red) and PKM2 (green) 
in siRNA-silenced confluent HUVECs. Scale bar, 10 µm. (K and L) Mean fluorescent intensity (M.F.I.) of 
PKM2 (K) and VE-cadherin (L) at the junctions of siRNA-silenced confluent HUVECs; means ± SEM, n = 5 
independent experiments, ****p < 0.0001 by Mann-Whitney test. (M) Percentage of discontinuous VE-
cadherin-junctions; means ± SEM, n = 3 independent experiments, *p < 0.05 by unpaired Student t-test. (N) 
Immunofluorescence of plakoglobin (red) and nuclei (blue, Hoechst) in siRNA-silenced confluent HUVECs. 
Scale bar, 10 µm. (O) Change in trans-endothelial electrical resistance (TEER) across monolayers of siRNA-
silenced HUVECs left untreated or treated with 1 μM S1P for 3 hours; means ± SEM, n = 3 independent 
experiments, ns non-significant, *p < 0.05 by one-way ANOVA with Sidak post-test. See related Figure S2.
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Figure 4. PKM2 silencing leads to misorientation and impaired collective migration of ECs. (A) 
Immunofluorescence of PKM2 (green) and Ki67 (red, proliferation) in siRNA-silenced HUVECs 16 hours after 
scratch wounding. Scale bar, 50 µm. W, wound. (B) Western blot and quantification of PKM2 expression in 
silenced-HUVEC cells at the end of the scratch assay; means ± SEM, n = 3 independent experiments, *p < 0.05 
by Mann-Whitney test. MW, molecular weight (C and D) Percentage of wound closure (C) and of Ki67-positive 
cells (D) 16 hours after scratch wounding; means ± SEM, n = 3 independent experiments, ns non-significant 
and **p < 0.01 by unpaired Student t-test. (E) Immunofluorescence of VE-cadherin (green), PKM2 (blue), 
and GM130 (red) in siRNA-silenced HUVECs 16 hours after scratch wounding. W, wound. White and red 
arrows indicate cell polarization toward and away from the wound, respectively; Scale bar, 10 µm. (F and G) 
Percentage of discontinuous junctions (F) and of endothelial cells oriented against the wound (G) in siRNA-
silenced HUVECs 16 hours after scratch wounding; means ± SEM, n = 3 independent experiments, **p < 0.01 
by unpaired Student t-test. (H) Single-cell track analysis of siRNA-silenced HUVECs in the scratch assay; n = 3 
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tumor-cell proliferation depending on PKM1 expression, such that if PKM1 was expressed, proliferation capac-
ity was reduced27. Moreover, PKM2-deficient primary cells derived from this mouse model also showed com-
pensatory PKM1 upregulation, leading to impaired cell proliferation28. Corroborating this, proliferating embryo 
regions which would normally express PKM2 have been shown to initiate PKM1 expression in PKM2-null 
embryos, which is accompanied by a slowing of cell division and unexpected normal embryonic development45. 
In our experiments, PKM1 expression did not increase in PKM2-silenced ECs, possibly explaining the lack of any 
impact on EC proliferation. This is in contrast with recent reports claiming that PKM2 knockout reduced EC pro-
liferation in which the compensatory increase of PKM1 might be a confounding factor to interpret direct PKM2 
effects in EC proliferation46,47. Our findings further support the functional segregation of metabolic enzymes in 
regulating the spectrum of EC responses required for angiogenesis14.
PKM2 has been reported to both favor and decrease cancer cell migration48–50. Our study is in line with 
recent reports on the requirement of PKM2 for endothelial cell migration46,47. Other glycolytic enzymes have 
been shown to positively regulate cell migration, for example PGK1 in tumor cells51, PFKFB3 in ECs11, and HK2 
in lymphatic ECs13. Our findings show that PKM2 activity is required for EC collective migration, evidenced 
by impaired EC orientation and migration in the scratch assay and by the reduced 3D sprout-length and retinal 
vascular radial outgrowth without changes in proliferation.
Our findings also provide insight into how differential VE-cadherin dynamics and mosaic junction activity 
influence productive angiogenesis. PKM2 loss reduced junctional VE-cadherin and increased the proportion of 
active/unstable junctions, thus compromising the balance between inactive/stable and active/unstable junctions 
and destabilizing the endothelial barrier. These findings thus indicate that PKM2 is primarily required for proper 
VE-cadherin–mediated endothelial cell-junction stability. The ‘patching algorithm’ developed by Bentley35 has 
been especially useful in gaining insight into this process because it gives not only absolute numbers of stable 
and unstable junctions but also their clustered distribution. Recent studies into the role of EC junctions in angi-
ogenesis provide evidence that they not only constitute a barrier and a signaling platform but also fine-tune 
cellular processes of paramount importance for efficient directionality and expansion of capillary sprouts. For 
example, VE-cadherin fingers from the pulling EC are essential for collective and cohesive EC migration during 
sprout extension36; we confirm that defective VE-cadherin at junctions by PKM2 absence or inhibition results 
in impaired collective migration. Our findings also demonstrate that VE-cadherin internalization which is 
required for EC junction stability and remodeling, depends on PKM2 activity, likely through the provision of 
ATP for vesicle movement20 since VEFGA-induced VE-cadherin endocytosis is clathrin-dependent and thus 
ATP-consuming52. PKM2-generated ATP at junctions could additionally favor actomyosin contractility or the 
phosphorylation of enzymes implicated in cell-cell junction stabilization or remodeling6,53,54.
PKM2 silencing also led to reduced numbers of filopodia in the endothelial tip cells. Since filopodia positively 
regulate cell motile velocity, they ultimately affect sprouting55,56. This phenotype could be related to the reported 
association of PKM2 with F-actin34 since although our live imaging data favor the hypothesis of a primary impact 
of PKM2 inhibition on VE-cadherin internalization and JAIL formation, we cannot rule out an additional action 
on F-actin dynamics. Thus, PKM2 could provide ATP near to dynamic membrane protrusions such as filopodia 
and lamellipodia, and together with other enzymes such as PKFB3 form the actin-bound ‘glycolytic hub’ proposed 
by Carmeliet’s group19,57. Whether a similar complex also forms at EC junctions deserves however further analysis.
VE-cadherin is the master regulator of EC junction formation and stability, but recently new players have been 
identified. For example, vinculin restrains junctions during remodeling and pacsin2 inhibits asymmetric VE-cadherin 
internalization, protecting EC-junction integrity from mechanical forces; moreover, the YAP/TAZ pathway increases 
VE-cadherin turnover, promoting cell migration while maintaining barrier function58–60. EC junctions, and particu-
larly VE-cadherin, are thus dynamically and exquisitely remodeled during angiogenesis. Nevertheless, in spite of the 
recognized importance of metabolic pathways in EC responses, very little is known about how metabolism impacts EC 
junction stability and dynamics. Only the glycolytic enzyme PFKBF3 has been shown to modulate EC junctions, by an 
as-yet unknown mechanism61. Although PKM2 loss has been claimed to alter EC junction stability by non-enzymatic 
actions46,47, to our knowledge the present report is the first to demonstrate the presence of a pool of a glycolytic enzyme 
nearby the junctions of confluent ECs by immunostaining and biochemical approaches. Moreover, we show that PKM2 
is required for ATP-dependent processes as VEFGA-induced clathrin-mediated VE-cadherin endocytosis44 and thus 
for junction stability41. The fact that PKM2 at the CSK-junction enriched compartment has higher pyruvate kinase 
activity than cytosolic PKM2 suggests that the activity of the CSK-junction–associated PKM2 is positively regulated 
by mechanisms that may involve tetramer stabilization upon F-actin binding, similar to what occurs with PFKFB3 at 
lamellipodia57. The activity of PKM2 tetramers at cell-cell junctions may also be regulated by local interaction with 
allosteric activators or posttranslational modifications62. This also raises the question of how PKM2 traffics toward and 
locates at the plasma membrane. PKM2 interacts with huntingtin63, which associates with GAPDH in vesicles traveling 
along microtubules in neurons20, and it has recently been found enriched at these motile vesicles64. It is therefore possi-
ble that PKM2 also traffics on microtubules alone or together with GAPDH in ECs. Furthermore, we demonstrate that 
VE-cadherin is required for PKM2 localization at the endothelial junctions. Whether PKM2/VE-cadherin association 
is direct or mediated by an intermediate protein as β-catenin, a renowned VE-cadherin partner also shown to interact 
with PKM2 in other contexts65, deserves further investigation.
independent experiments. Black and red tracks indicate cells migrating toward and against the wound. (I and J) 
Velocity, linear (Euclidean) distance and directionality of single cells moving against (I) and toward the wound 
(J); means ± SEM, n = 50–60 cells from 3 independent experiments, ns non-significant and *p < 0.05 by Mann-
Whitney test. (K) Representative single-cell tracks of three adjacent siRNA-silenced ECs migrating during the 
scratch assay. See related Figure S3 and Movies S1 and S2.
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The defective vasculature of PKM2-silenced and shikonin-treated retinas in postnatal mice supports the 
recent evidences of a requirement for PKM2 in angiogenesis in vivo46,47. In our context, the vascular impairment 
affected radial growth and filopodia number without influencing EC proliferation, and the phenotype correlates 
Figure 5. PKM2 is required for endothelial-cell junction remodeling during sprouting angiogenesis in vitro 
and in vivo. (A) Scheme illustrating the patching algorithm classification of VE-cadherin active (unstable)/
inactive (stable) junctions adapted from Bentley et al., 2014. (B) Immunofluorescence of VE-cadherin (green, 
top) in 3D spheroid sprouts. Pseudo-colored images according to the patching algorithm classification are 
shown below. Scale bar, 10 µm. (C and D) Percentage of VE-cadherin active and inactive junction patches (C) 
and their ratio (D) in 3D spheroid formed by siRNA-silenced HUVECs; means ± SEM, n = 3 independent 
experiments. **p < 0.01 by Mann-Whitney test. (E) Immunofluorescence of VE-cadherin (green, top) in P6 
mouse whole-mount retinas 72 hours after intraocular siRNA injection. Pseudo-colored images according to 
the patching algorithm classification are shown below. Scale bar, 10 µm. (F and G) Percentage of VE-cadherin 
active and inactive junction patches (F) and their ratio (G) in P6 mouse retinas 72 hours after siRNA injection; 
means ± SEM, n = 4 mice, *p < 0.05 by Welch’s test.
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with the altered ratio of stable and unstable EC junctions. The possible clinical application of these findings to 
stimulate or inhibit PKM2 activity in disease needs to be carefully considered. In pathological angiogenesis, the 
proportion of active junctions increases (with a discontinuous pattern)35, and sprouting defects are related to 
Figure 6. PKM2 activity is required for ATP levels at EC junctions. (A) Extracellular acidification 
ratio (ECAR) in HUVECs transfected with control or PKM2 siRNA; means ± SEM, n = 3 independent 
experiments.**p < 0.01 by Mann-Whitney t-test. (B) Total ATP per ng protein in HUVECs transfected with 
control or PKM2 siRNA, quantified as fold induction (F.I.) versus control; means ± SEM, n = 8 independent 
samples analyzed in 2 sets of experiments. *p < 0.05 by Mann-Whitney t-test. (C and D) Baseline (C) 
and maximum (D) oxygen consumption ratio (OCR) in HUVECs transfected with control or PKM2 
siRNA; means ± SEM, n = 3 independent experiments, ns non-significant by Mann-Whitney t-test. (E) 
Immunofluorescence of PKM2 (green), VE-cadherin (red) and F-actin (grey) in HUVECs permeabilized or 
not with 0.01% saponin. Merged image of green and red channels is also shown. Scale bar, 10 µm. (F) Western 
blot of PKM2 in fractions extracted from HUVECs with 0.01% saponin (cytosol enriched) or 0.01% + 0.1% 
saponin (cytoskeleton (CSK)-junction enriched). VE-cadherin and β-actin are included as markers of cell 
junctions and cytoskeleton. MW, molecular weight. (G and H) Pyruvate kinase activity (G) and ATP amount 
(H) normalized to protein content in fractions extracted as in F from HUVECs transfected with control or 
PKM2 siRNA; means ± SEM, n = 8 independent samples analyzed in 2 sets of experiments, ns non-significant, 
*p < 0.05 and **p < 0.001 by unpaired Student t-test. (I) Images of the GFP, OFP and OFP/GFP channels from 
live microscopy of GO-ATeam1-transduced HUVECs silenced with control or PKM2 siRNA. The yellow and 
white lines mark in the GFP channel the cytosol and EC junction areas for OFP/GFP quantification. Scale 
bar, 10 µm. (J) OFP/GFP intensity ratio at cytosol, EC junctions and EC junction/cytosol of GO-ATeam1-
transduced HUVECs transfected with control or PKM2 siRNA as fold induction respect control siRNA cells in 
each experiment, means ± SEM, n = 100–109 cells from 5 independent experiments analyzed per condition, 
****p < 0.0001 by unpaired Student t-test. See related Figures S4, S5 and S6.
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impaired endothelial junctions66,67. In contrast, there is no evidence that an increased proportion of inactive junc-
tions (with a continuous pattern) has any effect on angiogenesis68. PFKFB3, a key glycolysis regulator, has been 
proposed as a target for inducing normalization of EC junctions61,69. In a model of high-dose-VEGFA–induced 
pathological retinal angiogenesis35,70, the PFKFB3 inhibitor 3PO decreased glycolysis by 15% and normalized the 
vasculature69. This effect was also observed in 3PO-treated tumor ECs61. However, treatment of ECs with higher 
3PO concentrations, inhibiting glycolysis by 40%, induced an increase in discontinuous junctions rather than 
vessel normalization71. This finding underlines the importance of the level of glycolysis inhibition in determining 
the final angiogenic outcome. In line with this, we observed increased instability of VE-cadherin EC junctions 
upon PKM2-silencing, which also decreases glycolysis by 40%, and with the global glycolysis inhibitor 2-DG, 
which almost abolishes glycolysis. Moreover, high concentrations of exogenous ATP also increase discontinuous 
Figure 7. PKM2 is required for junction dynamics and VE-cadherin internalization. (A and B) Still images 
from live microscopy of HUVECs transduced with lentivirus coding for VE-cadherin-EGFP (A) or LifeAct-
EGFP (B) for 10 min prior and after addition of 20 ng/ml of VEGFA; untreated and shikonin-treated cells are 
shown. Scale bar, 5 µm. (C) Number of inter-cellular gaps at junctions of VE-cadherin-transduced HUVEC 
along time. (D and E) Number of JAIL and of VE-cadherin plaques at the lateral junctions of LifeAct-EGFP 
and VE-cadherin-EGFP-transduced HUVECs, respectively; means ± SEM, n = 6 junctions for 2 independent 
experiments. (F) Immunofluorescence of VE-cadherin (red) and Hoechst (blue, nuclei) before or after acid 
wash in HUVECs transfected with control or PKM2 siRNA and treated with 20 ng/ml VEGFA for 15 minutes. 
Scale bar, 10 µm. (G) Internalized VE-cadherin positive area per number of cells in arbitrary units (A.U.); n = 3 
independent experiments, **p < 0.01 by one-way ANOVA with Sidak post-test. See related Figure S6 and 
Movies S5–S8 and S11–S14.
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junctions and decrease TEER in brain endothelial cells72. Together, these observations suggest a dual effect of 
ATP, with a precisely adjusted level required for proper dynamic EC junction rearrangement. Metabolic regu-
lation of EC junctions thus appears to be a complex process that depends on the quantity of ATP produced, the 
step in the glycolytic pathway involved, and where the implicated enzyme is located. Given the likelihood that 
glycolysis inhibition will have a ‘dose response’ effect on angiogenesis, studies are warranted to address the impact 
of PKM2 silencing or inhibition on pathological angiogenesis.
Our findings show that PKM2 makes an essential contribution to angiogenesis in vitro and in vivo by provid-
ing ATP for the regulation of VE-cadherin internalization and EC junctions. In light of the importance of PKM2 
in cancer and other diseases such as diabetes, our findings provide information relevant to the development of 
PKM2-based therapeutic strategies.
Experimental Procedures
Antibodies and reagents. The following antibodies were used: PKM2 (#4053) and PKM1 (#7067) from 
Cell Signaling; β-actin (A441) and GAPDH (G9545) from Sigma; Rho-GDI (sc-360) and VE-cadherin (sc-6458) 
from Santa Cruz Biotechnologies; VE-cadherin (555289), plakoglobin (610254), GM130 (610605), and EEA1 
(610685) from BD Pharmingen; Ki67 (IR626) from DAKO; and Ki67 (ab16667) from Abcam. F. Sánchez-Madrid 
(Centro Nacional de Investigaciones Cardiovasculares, CNIC, Madrid) kindly provided the anti-VE-cadherin 
TEA1/31 antibody73. IsolectinB4 (B-1205) was from Vector. Phalloidin, streptavidin, and Alexa Fluor second-
ary antibodies and Hoechst were from Life Technologies, and HRP secondary antibodies were from Jackson 
Immunoresearch Laboratories.
2-DG, ATP, FCCP, EDTA, glucose, luciferin, luciferase, mitomycin C, saponin, and shikonin were from 
Sigma Aldrich; cytodex3 from Amersham; fibrinogen, thrombin, and methylcellulose from Merck-Millipore; 
fluoromount-G from Southern Biotech; Ibidi chambers from Ibidi; phosphatase and proteinase inhibitors from 
Roche; Optiprep from AxisShield; and S1P from Cayman.
Cell cultures. HUVECs (Lonza) were cultured in plastic dishes (Falcon and Ibidi) coated with 0.5% gelatin 
and were used for experiments at P3-P4. HUVECs were grown and maintained in 199 cultured medium (Lonza) 
supplemented with 20% FBS (Gibco), 100 U/ml penicillin, 100 µg/ml Streptomycin, 2 mM L-Glutamine, and 
10 mM Hepes (all from Lonza), and ECGS-heparin factors (Promocell). For angiogenesis experiments, EGM-2 
medium (Promocell) was used. HUVECs were serum-starved for at least 3 hours before experiments, and main-
tained without FBS throughout treatments.
Fibroblasts were provided by M. A. del Pozo (Centro Nacional de Investigaciones Cardiovasculares, CNIC, 
Madrid) and were cultured in IMDM medium supplemented with 10% FBS,100 U/ml penicillin, 100 µg/ml strep-
tomycin, 1mM L-glutamine, 10 mM Hepes and 1 mM Na-pyruvate.
Mouse lung endothelial cells (MLECs) isolated from C57BL/6 mice and VE-cadherin-null mouse endothelial 
cells provided by E. Dejana (FIRC Institute of Molecular Oncology, Italy) were cultured as described previously6.
Mouse retinal vasculature model. Retinal angiogenesis was assessed in C57BL/6 mice. Mice were 
housed and animal experiments performed under specific pathogen-free conditions at the Animal facility of 
Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), and in strict accordance with the insti-
tutional guidelines. Animal procedures were approved by the Committee on the Ethics of Animal Experiments 
of the CNIC (Permit Number: CNIC-01/13) and by the corresponding legal authority of the local government 
‘Comunidad Autónoma’ of Madrid (Permit Number: PROEX 34/13). Animal studies were conformed to directive 
2010/63EU and recommendation 2007/526/EC regarding the protection of animals used for experimental and 
other scientific purposes, enforced in Spanish law under RD1201/2005. Mice were fed ad libitum with standard 
chow (2108 Teklad global, Harlan Interfauna Iberica S.L.).
Animals were intravitreally injected with 1 µg of siRNA in Lipofectamine RNAimax at P3 and sacrificed at P6. 
For pharmacological inhibition of PKM2 activity, 100 µM of shikonin (or DMSO control) were injected at P5, and 
the mice were sacrificed at P6. Eyes were fixed overnight in 2% paraformaldehyde (PFA) and then enucleated, and 
retina was isolated as reported74.
siRNA interference and plasmid and lentivirus transfection. Silencer™ Select siRNA oligonucleotides 
against isoform M2 of pyruvate kinase (Thermo Fisher) were transfected using Lipofectamine RNAimax (Thermo 
Fischer) in Optimem medium (Lonza) at a final siRNA concentration of 10 nM. Oligonucleotide sequences were 
5′CCAUAAUCGUCCUCACCAA dTdT 3′ for human PKM2 and 5′ GUGCGAGCCUCCAGUCACU dTdT 3′ 
Ambion™ In Vivo for mouse PKM2. Control siRNA was from Ambion™ In Vivo.
Lentivirus containing Go-ATeam140 was generated at VRC in Leuven Belgium or at the CNIC 
Viral Vectors  Unit using the particles provided by Esteban Veiga-Chacón (Centro Nacional de 
Biotecnologia, CNB-CSIC, Madrid). Lentiviruses were added to cells at a M.O.I. of 10.
Lentivirus containing VE-Cadherin-EGFP and LifeAct-EGFP (kindly provided by Prof. Hans Schnittler from 
the Universität of Münster, Germany) was generated at the CNIC Viral Vectors Unit. Lentiviruses were added to 
cells at a M.O.I. of 10.
Scratch assays. Confluent HUVECs were serum-starved for 3 hours and a wound was made with a plastic 
pipette tip. After washing the cells with PBS, migration was stimulated by adding medium containing 5% FBS. In 
the experiments in which proliferation was inhibited, cells were treated before and throughout the experiment 
with 2 μg ml−1 mitomycin C, 1 µM Shikonin or corresponding vehicle control. Migration was quantified as the 
proportion of the initial wound area remaining uncovered at the end of the experiment.
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For collective migration, time-series pictures were taken every 20 minutes during 16 hours; only those experi-
ments in which the endothelial monolayer remained confluent >80% after siRNA silencing or shikonin treatment 
were included in the analysis.
Cell count assay. Cells were seeded at equal density in P96 wells. On each day of the experiment, cells in 
individual wells were detached and counted.
Microbead spheroid assay. Cytodex3 microbeads were purchased from Amersham, and the protocol was 
performed as previously described75.
Transendothelial electrical resistance (TEER). TEER assays with an electric cell-substrate impedance 
sensing system (ECIS 1600R; Applied Biophysics76;) were performed as described77,78. The S1P-induced TEER 
increase was expressed as the percentage difference in resistance between unstimulated ECs and ECs stimulated 
with S1P for 3 hours.
Immunofluorescence. Cells were fixed for 15 min in 4% PFA, blocked and permeabilized in 0.01% Triton 
X-100 2% BSA in PBS. Primary antibodies were incubated overnight in a cold room and secondary antibodies for 
1 hour at 37 °C. Cell orientation was quantitated according to the relative position of Golgi versus nucleus toward 
or against the wound (±180°).
Fibrin gels were fixed in 1% PFA PBS for 30 minutes and washed. Gels were then permeabilized and blocked 
for 2 hours in blocking and permeabilization (BP) buffer (2% BSA, 0.3% Triton X-100, 0.3 M glycine, 0.2% azide, 
and 1% goat serum in PBS). Gels were incubated with primary antibodies overnight in the same buffer. The next 
day, gels were post-fixed in 4% PFA for 15 minutes. After a wash and 30 minutes in BP buffer, gels were incubated 
with secondary antibodies.
Retinas were blocked and fixed overnight in 2% BSA, 1% goat serum, 0.2% deoxycholate, 0.5% Triton X-100, 
and 0.2% azide in PBS. The next day, primary antibodies were added and incubations were maintained over-
night. Retinas were then incubated overnight with Isolectin B4 in PBLEC buffer (1 mM MgCl2, 1 mM CaCl2, 
and 0.1 mM MnCl in PBS pH 6.8). Finally, secondary antibodies were added and incubations were maintained 
overnight. All preparations were mounted in Fluoromount-G.
Proximity ligation assay (PLA). HUVECs were grown to confluence, fixed and permeabilized. PLA was 
performed next day following the manufacturer’s instructions (Duolink PLA, Sigma Aldrich). Briefly, samples 
were blocked with the blocking solution for 30 min at 37 °C and incubated overnight with the primary antibodies, 
rabbit anti-PKM2 (#4053, Cell Signalling) and goat anti-VE-cadherin (sc-6458, Santa Cruz biotechnology), at 
4 °C. The following day, the samples were washed and incubated for 1 h at 37 °C with PLA probes for rabbit and 
goat antibodies. After washing, samples were incubated with the ligase for 30 min at 37 °C, washed again and 
incubated with the polymerase for 100 min at 37 °C. Finally, the samples were washed, dried completely and 
mounted in Duolink In Situ Mounting Medium with Hoechst. Rabbit and goat IgGs were used as negative control.
Cell live imaging. Live imaging was performed with a LSM700 Zeiss confocal microscope (Carl Zeiss) at a 
constant temperature of 37 °C and 5% CO2. PKM2-GFP was detected with 488 nm excitation and 510 nm emis-
sion. Go-ATeam1 was detected with 488 nm excitation and emission at 510 nm and 560 nm. VE-cadherin-GFP 
and LifeAct-GFP were detected with 488 nm excitation and 510 nm emission, time-series images were taken 
every minute for 15 minutes and after addition of 50 ng/ml of VEGFA for a further 15 min. Image analysis was 
performed using Fiji software.
Membrane subfractionation. The membrane subfractionation protocol was performed as previously 
described79. Briefly, HUVEC membrane fractions were obtained and separated by ultracentrifugation on a dis-
continuous Optiprep density gradient (AxisShield). Protein fractions were precipitated, resuspended in Laemmli 
buffer, resolved by SDS-PAGE, and analyzed by western blot.
Western blotting. Cells were lysed in RIPA buffer as described6. Retinas were isolated as reported80, and 
then RIPA buffer was added to the exposed vessels. Centrifugation was performed after 1 hour of incubation, and 
supernatant was recovered. Protein lysates were separated by 8% SDS-PAGE under reducing conditions. After 
transfer to a nitrocellulose membrane (Bio-Rad), blots were blocked with 5% BSA-PBS and incubated for 1 hour 
at room temperature (RT) with primary antibody diluted in 2% BSA-PBS. Membranes were then washed in 
0.2% Tween 20-PBS and incubated for 1 hour at RT with horseradish peroxidase-conjugated secondary antibody. 
Protein bands were visualized by enhanced chemiluminescence (ECL; GE Healthcare). Band intensities were 
analyzed with Fiji software.
Glucose and oxygen consumption. The extracellular acidification and oxygen consumption ratios 
(ECAR and OCR) were obtained in a Seahorse XF96 (Agilent), using glucose, oligomycin, FCCP and 2-DG, as 
described81.
ATP levels. ATP production in saponin-enriched fractions was measured by a kinetic luciferin-luciferase 
luminescence assay, and normalized to the protein concentration in each sample6. Briefly, fractions were diluted 
in buffer A (150 mM KCl, 25 mM Tris-HCl pH 7.4, 2 mM EDTA, 0.1% BSA, 10 mM KPO4, 0.1 mM MgCl2) with 
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0.15 mM diadenosine pentaphosphate and then buffer B (0.5 M Tris–acetate pH 7.75, 0.8 mM luciferin, 20 μg/ml 
luciferase) and 0.1 mM ADP were added before recording light emission in the luminometer.
Pyruvate kinase assay. PK activity was measured in saponin-permeabilized HUVEC fractions using a 
commercial kit from Biovision.
VE-cadherin internalization. Internalization assays were performed as previously described82. Briefly, to 
measure internalization of endogenous VE-cadherin, confluent HUVEC were incubated with the VE-cadherin 
antibody (TEA1/31) at 4 °C for 1 h in 1% BSA medium. Then, we rinsed the cells in cold culture medium to 
remove unbound antibody and treated them with 50 ng/ml of VEGFA for 30 min at 37 °C to allow the internaliza-
tion. Cells were acid-washed (2 mM PBS-glycine, pH 2.0) or washed with cold PBS 3 times for 10 min each (used 
as control) and fixed and processed for immunofluorescence.
Confocal image quantification. Images were obtained with a Zeiss LSM700 confocal microscope (Carl 
Zeiss Microscopy) and maximum intensity projections are shown in all figures unless otherwise indicated. For 
analysis of mean fluorescence intensity, regions of interest (ROIs) were selected around junctions with Fiji soft-
ware. For junction morphology analysis, we used reported criteria to distinguish discontinuous and continuous 
junctions83. For spheroid assays, mean length of sprouts and sprout number were analyzed in bright-field images 
with Fiji. Filopodia number was determined using phalloidin-stained F-actin. Data were normalized to cell 
length. For Go-aTeam1 analysis, the region of interest (ROI) for EC junctions was drawn ≤5 µm width around 
the cell-cell contacts defined by a 16 colors-pseudocolor plugin of Fiji software (validated by VE-cadherin stain-
ing). The cytosol ROI was defined as the rest of the cell.
Retinal parameters were quantified as described74,84. Radial growth was calculated as the average length in each 
lobule of one eye, from the optic nerve to the vascular front. Vascular density was calculated as the percentage of 
total area occupied by isolectin B4. Ki67 positive ECs were calculated as the percentage of Ki67 + ERG + cells of 
total ERG + cells, and normalized by Isolectin B4 area. Junction morphology was analyzed using the ‘patching 
algorithm’ implemented in MATLAB software35.
For VE-cadherin internalization experiments, images were taken using Nikon A1R confocal microscopy with 
a 40x objective and image analysis were performed using Fiji software.
For time-lapse scratch assay, images were taken with a Nikon time-lapse microscope with a 10x objective. 
Analysis of the tracking was done using Fiji with manual tracking plugin and Chemotaxis tool from ibidi.
Statistical analysis. Absolute values were represented for most of the quantitated parameters. In cases of 
high variability in such values among experiments, fold induction versus control was calculated for each exper-
iment as indicated in the corresponding legend. All values were analysed with Prism GraphPad. First all values 
were subjected to Grubbs’s outlier test (p < 0.05), and then D’Agostino-Pearson test for analysis of normal dis-
tribution was performed. The proper tests to compare samples were used as indicated in each figure legend. In 
general, for comparison of two samples, unpaired Student t-test was used in normal (Gaussian) data with equal 
variance, Welch’s test was used in normal (Gaussian) data with no equal variance and Mann-Whitney test for 
non-normal data; for comparison of three or more conditions, One-way ANOVA with Sidak-post test was used. 
Differences were considered significant at p < 0.05.
Data availability
All relevant data are available from the authors upon request.
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